Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GDF15 monoclonal antibody AV-380

A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-derived factor; PDF; placental bone morphogenetic protein; PLAB), with potential anti-cachexic activity. Upon administration, anti-GDF15 monoclonal antibody AV-380 specifically targets, binds to and inhibits the activity of GDF-15, a pro-inflammatory cytokine involved in cancer-induced cachexia. This may prevent or slow the effects of cachexia. GDF-15, a divergent member of the transforming growth factor-beta (TGF-beta) superfamily of cytokines, is upregulated in cancer-associated cachexia and immunosuppression in the tumor microenvironment (TME). It is associated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:AV 380
AV-380
AV380
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search